Exogenous IL-33 promotes tumor immunity via macroscopic regulation of ILC2s
Scientific Reports · 2024
DOI: 10.1038/s41598-024-77751-6 ↗Kurz gefasst
Fachartikel in der Zeitschrift Scientific Reports, 2024. Verfasst von Zhenchu Feng und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, The 2nd Affiliated Hospital of Harbin Medical University, 246 Xuefu Road, Harbin, 150086, China. Hauptthemen laut MEDLINE: Immunity, Innate, Interleukin-33, Lymphocytes, Melanoma. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Special fund of the basic research support program for outstanding young teachers in Heilongjiang Province.
Abstract (Originalsprache)
Interleukin-33 (IL-33) is a pleiotropic molecule that plays various roles in the body. However, how exogenous IL-33 changes the tumor immune microenvironment remains unclear. Our study revealed that exogenous IL-33 exerts anti-tumor effects and effectively suppresses the progression of subcutaneous melanoma. scRNA-seq analysis revealed that exogenous IL-33 reduced neutrophils accumulation, thereby improving the inhibitory immune environment. Flow cytometry analysis revealed that exogenous IL-33 significantly increased the proportion of eosinophils and group 2 innate lymphoid cells (ILC2s). In addition, we identified genes encoding major histocompatibility complex (MHC) class II molecules in this group of ILC2s, suggesting that ILC2s may play a role in antigen presentation. In Il7rCreArg1flox/flox mice, the decrease of ILC2s led to a reduction in the proportion of eosinophils. Furthermore, we found that exogenous IL-33 effectively promoted the differentiation of ILC2s and their accumulation in tumors, thereby enhancing the anti-tumor immune response. These findings may pave the way for developing new cancer immunotherapies that use IL-33 as an activator to enhance anti-tumor immune responses.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Surgery, The 2nd Affiliated Hospital of Harbin Medical University, 246 Xuefu Road, Harbin, 150086, China.
- Department of Gynecology and Obstetrics, The 2nd Affiliated Hospital of Harbin Medical University, Harbin, 150086, China.
- Department of Breast Surgery, Harbin Medical University Cancer Hospital, Harbin, 150081, China.
- Department of Microbiology, WU Lien-Teh Institute, Harbin Medical University, 157 Baojian Road, Harbin, 150086, China. 1004739098@qq.com.
- Department of Surgery, The 2nd Affiliated Hospital of Harbin Medical University, 246 Xuefu Road, Harbin, 150086, China. 13804517666@163.com.
Förderung
- Special fund of the basic research support program for outstanding young teachers in Heilongjiang Province
Zitieren
APA
Feng, Z., Kuang, Y., Qi, Y., Wang, X., Xu, P., & Chen, X. (2024). Exogenous IL-33 promotes tumor immunity via macroscopic regulation of ILC2s. Scientific Reports. https://doi.org/10.1038/s41598-024-77751-6
Vancouver
Feng Z, Kuang Y, Qi Y, Wang X, Xu P, Chen X. Exogenous IL-33 promotes tumor immunity via macroscopic regulation of ILC2s. Scientific Reports. 2024. doi:10.1038/s41598-024-77751-6
BibTeX
@article{Feng2024,
author = {Feng, Zhenchu and Kuang, Ye and Qi, Yuan and Wang, Xi and Xu, Peng and Chen, Xi},
title = {Exogenous IL-33 promotes tumor immunity via macroscopic regulation of ILC2s},
journal = {Scientific Reports},
year = {2024},
doi = {10.1038/s41598-024-77751-6}
}
EUVIMED